Loading...

SPRO SPERO THERAPEUTICS INC Financial Troubles 8-K Filing

SPR

SPR

SPERO THERAPEUTICS INC

(SPRO)

2025 8-K

Q1 Results Announcement

Q4 Results Announcement

Management Change

Milestone Payment Announcement

Quarterly Results

Product Expansion

Financial Statements

Earnings Report

SEC Investigation

Q3 Earnings Report

Workforce Reduction

Investor Update

Earnings Reports

Amendment to Stock Incentiv...

Annual Meeting Announcement

Financial Results Announcement

Departure of Directors or C...

Presentation Update

Financial Condition

Clinical Trial Announcement

Earnings Reports

Appointment of Esther Rajav...

Amendment to Filing

Stock Incentive Plan Amendment

Earnings Reports

FDA Agreement for Phase 3 C...

Earnings Report

Financial Results Announcement

Appointment of Chief Operat...

Financial Condition

External Links:

On December 19, 2025, Spero Therapeutics announced that GlaxoSmithKline filed a resubmission for a New Drug Application for tebipenem HBr, which will trigger a $25 million milestone payment to Spero expected in early 2026.

AI Assistant

SPERO THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.